Elypta measures the GAGome – a standardized profile of free glycosaminoglycans in urine and plasma. The same measurement can be read for different clinical questions, but each question needs its own score, its own study population and its own evidence.
Our pipeline includes:
Can a GAGome score improve on established risk models when deciding who is offered LDCT screening?
Can a GAGome score predict who will develop cancer over the next five years, among people who currently have none?